The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th - 8th March 2024 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Biosample Operations Specialist, Roche
Associate Director, Translational Biomarkers & Bioanalysis, UCB
Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis, UCB
Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB
Head, Early Detection and Biomarkers, The Cameroon Consortium for Translational Cancer Research
Scientific Director, Bioinformatics, Evaxion Biotech A/S
Scientist, Cancer Immunotherapy, Numab Therapeutics AG
Founder, CEO, Predicine